Mochida Pharmaceutical Co., Ltd.

Ricoh Company, Ltd.

Other

Kyowa Hakko Kogyo Co., Ltd.

Showa Denko Materials Co., Ltd.

Resonac Corporation

Kyowa Hakko Chemical Co., Ltd.

Tsutomu Satoh

Tatsuya Tomura

Ikuo Shimizu

Yasunobu Ueno

Soh Noguchi

Noboru Sasa

Yasuhiro Higashi

Hiroshi Toyoda

Shoji Furusako

Motoharu Kinugasa

Shiho Yamada

Yukiyoshi Ito

Tomohiro Narumi

Hideyuki Tsuchiya

Masanori Ikuta

Kenji Mutoh

Takashi Kudoh

Tetsuo Iwama

Hideharu Uchida

Fumihiko Saitoh

Hiroshi Nagasue

Kento Hoshi

Yoshitaka Maeda

Yasushige Akada

Tomoyuki Kamino

Keiko Ichinose

Yuji Kawada

Naoto Kosuga

Daido Hotta

Shohji Maruyama

Kazukiyo Nagai

Tohru Yashiro

Tomomi Ishimi

Jie Li

Shingo Sato

Yutaka Kato

Masaakira Umehara

Shoji Maruyama

Kiyoshi Mizuguchi

Nobuo Ohzawa

Fenglai Sun

Kazuyuki Matsuura

Shuhei Ohnishi

Jinguang Lin

Chunbo Sha

Ken-ichi Amano

Keita Suga

Yonghui Ge

Yasuhiro Nakai

Motohiro Isaka

Yanliang Chen

Hideaki Ohba

Bin Zhao

Xiaomin Gu

Jian Luo

Chuan Chen

Xiaofei Cai

Jiajie Ye

Baoquan Sun

Ken-Ichi Amano

Shiho c/o Yokkaichi Research Lab Yamada

Hiroshi c/o Yokkaichi Research Lab Toyoda

Motoharu c/o Yokkaichi Research Lab Kinugasa

Ikuo c/o Yokkaichi Research Laboratories Shimizu

Provided are a novel crosslinked alginic acid, a crosslinked alginic acid structure, etc., by performing a crosslinking reaction using alginic acid derivatives represented by formula (I) and formula (II). As a result, a novel crosslinked alginic acid, crosslinked alginic acid structure, etc., are provided.

Crosslinked alginic acid structure

There has been demand for an additional method for producing antibodies. The present invention provides: a polymer-coated crosslinked alginate gel fiber in which a core layer containing a crosslinked alginate gel and either antibody-producing cells (e.g., antibody-producing CHO cells) or bioactive-substance-producing cells (e.g., MIN6 cells derived from pancreatic β cells) is coated with a cationic polymer; and a method for producing antibodies, a bioactive substance, etc., using the fiber.

Polymer-coated crosslinked alginate gel fiber

The present invention provides, a novel method for producing a compound represented by formula (I) and a novel method for producing a compound represented by formula (B) or a salt thereof, which are intermediates in the production of formula (I).

Method for producing heterocyclidene acetamide derivative

Provided are type I, III, V and VI crystals of 1-((1R,2R)-2-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)-3-(5-methyl-6-(2-methylpyrimidin-5-yl)-2-phenylpyridin-3-yl)urea which are useful as bulk pharmaceutical crystals. Also provided are type I, III, V and VI crystals of 1-((1R,2R)-2-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)-3-(5-methyl-6-(2-methylpyrimidin-5-yl)-2-phenylpyridin-3-yl)urea having excellent TrkA inhibitory effect, medicines and medicinal composition containing these crystals, and a method for producing these crystals.

Crystals of tetrahydronaphthyl urea derivative

A negative electrode material for a lithium-ion secondary cell, comprising carbon particles having an oxygen content of 0.15% by mass or less.

Negative electrode material for lithium-ion secondary cell, method for manufacturing negative electrode material for lithium-ion secondary cell, negative electrode material slurry for lithium-ion secondary cell, negative electrode for lithium-ion secondary cell, and lithium-ion secondary cell

The present invention provides alginic acid derivatives represented by formula (I) and formula (II), and a novel crosslinked alginic acid obtained by carrying out a Huisgen reaction using an alginic acid derivative of formula (I) and an alginic acid derivative of formula (II). There are thereby provided novel alginic acid derivatives and a novel crosslinked alginic acid.

Crosslinked alginic acid

An anode material for a lithium ion secondary battery including a carbon material satisfying the following (1) to (3), (6), and (7):

Anode material for lithium ion secondary battery, method of producing anode material for lithium ion secondary battery, anode for lithium ion secondary battery, and lithium ion secondary battery

The present invention provides: an alginic acid derivative having a photocrosslinking group represented by general formula (1) for a portion of a carboxyl group of alginic acids, and a photocrosslinking alginic acid structure which is produced using this alginic acid. Due to this configuration, a novel alginic acid derivative is provided. 

Photocrosslinkable alginic acid derivative

The present invention provides alginic acid derivatives having a group represented by general formula (I) or general formula (II) (the right side of the dashed line is excluded in each formula) at a portion of the carboxyl groups in an alginic acid. Novel alginic acid derivatives are thereby provided. 

Reactive alginic acid derivatives

A negative electrode material for a lithium-ion secondary battery contains graphitic particles of which a standard deviation of circularity at a cumulative frequency ranging from 10% by particle to 90% by particle from the lower circularity, determined by a flow-type particle analyzer, is from 0.05 to 0.1.

Negative electrode material for lithium ion secondary battery, negative electrode for lithium ion secondary battery, and lithium ion secondary battery

The present invention provides a type I crystal of (E)-2-(7-trifluoromethyl-chroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide having excellent TRPV1 antagonistic activity, a drug and a pharmaceutical composition containing this crystal, and a method for producing the crystal. The present invention provides a type I crystal of (E)-2-(7-trifluoromethyl-chroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide that is excellent in at least one feature selected from the group consisting of storage stability, photostability and thermodynamic stability, that can be preferably obtained with industrially high reproducibility, yield and purity, and that is useful as a crystal of an active pharmaceutical ingredient.

Crystal of a heterocyclidene acetamide derivative

The present invention provides a method for manufacturing a compound represented by formula (I). With this method, provided are a method for manufacturing a 4-heteroaryl-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-1H-pyrazole-5-carboxylic acid amide derivative; and an intermediate for this manufacturing method. 

Pyrazole derivative manufacturing method

The present invention provides a method for manufacturing a compound represented by formula (I). With this method, provided is a method for manufacturing a 4-substituted-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-1H-pyrazole-5-carboxylic acid amide derivative; or an intermediate for this manufacturing method. 

Growing community of inventors

Tokyo, Japan

Tsutomu Satoh